HC Wainwright Issues Negative Estimate for Invivyd Earnings

Key Points

• HC Wainwright analysts revised their Q3 2025 earnings estimates for Invivyd, projecting a loss of ($0.08) per share, down from a previous estimate of ($0.01).
• D. Boral Capital lowered its target price for Invivyd from $9.00 to $3.00, maintaining a "buy" rating.
• Invivyd shares recently traded at $0.5710, experiencing a decline of 1.7% and reflecting significant volatility over the past year.

Invivyd, Inc. (NASDAQ:IVVD - Free Report) - Research analysts at HC Wainwright dropped their Q3 2025 EPS estimates for Invivyd in a research report issued on Monday, August 18th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.08) for the quarter, down from their prior forecast of ($0.01). HC Wainwright currently has a "Buy" rating and a $5.00 target price on the stock. The consensus estimate for Invivyd's current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Invivyd's Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.40) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at $0.00 EPS, FY2026 earnings at ($0.15) EPS and FY2027 earnings at $0.12 EPS.

Separately, D. Boral Capital lowered their target price on shares of Invivyd from $9.00 to $3.00 and set a "buy" rating on the stock in a report on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $3.85.

Invivyd Stock Performance

IVVD traded down $0.0078 during trading on Wednesday, reaching $0.5201. 1,591,878 shares of the stock were exchanged, compared to its average volume of 1,100,347. The stock has a market cap of $62.49 million, a P/E ratio of -0.57 and a beta of 0.51. Invivyd has a twelve month low of $0.3546 and a twelve month high of $2.74. The stock's 50 day moving average price is $0.73 and its two-hundred day moving average price is $0.82.

Invivyd (NASDAQ:IVVD - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.08). Invivyd had a negative net margin of 238.33% and a negative return on equity of 177.89%. The business had revenue of $11.79 million during the quarter, compared to analyst estimates of $23.16 million.

Hedge Funds Weigh In On Invivyd

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its position in Invivyd by 644.1% during the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock worth $114,000 after purchasing an additional 222,375 shares during the period. Two Sigma Advisers LP boosted its position in Invivyd by 1,276.5% during the fourth quarter. Two Sigma Advisers LP now owns 304,200 shares of the company's stock worth $135,000 after purchasing an additional 282,100 shares during the period. Mithril II GP LP bought a new position in Invivyd during the fourth quarter worth $4,981,000. Deutsche Bank AG boosted its position in Invivyd by 35.2% during the fourth quarter. Deutsche Bank AG now owns 874,406 shares of the company's stock worth $385,000 after purchasing an additional 227,463 shares during the period. Finally, Two Sigma Investments LP boosted its position in Invivyd by 125.3% during the fourth quarter. Two Sigma Investments LP now owns 367,100 shares of the company's stock worth $163,000 after purchasing an additional 204,188 shares during the period. 70.36% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Invivyd news, insider Jill Andersen sold 49,402 shares of Invivyd stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total transaction of $28,159.14. Following the completion of the transaction, the insider directly owned 84,446 shares of the company's stock, valued at $48,134.22. The trade was a 36.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 277,654 shares of company stock worth $167,215 over the last three months. Insiders own 25.40% of the company's stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.